Rechallenge of drugs in the era of targeted therapy
Mené sur 81 patients atteints d'une tumeur stromale gastrointestinale métastatique ou non résécable ayant progressé après un traitement par imatinib et sunitinib, cet essai coréen de phase III évalue, du point de vue de la survie sans progression, l'intérêt de redémarrer un traitement par imatinib (durée médiane de suivi : 5,2 mois)
Switching of treatment after disease progression is a basic principle for cancer chemotherapy, because tumours progressing on therapy are thought to change permanently and become refractory to the treatment with associated resistance mutations either by selection pressure of previous therapy or by spontaneous acquisition of resistance. Progressive disease is used as a synonym of drug resistance and non-cross resistant drugs are required for subsequent therapy. After completion of standard treatm ...
The Lancet Oncology , commentaire, 2012